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ddictions are among the world's major health
problems,both in terms of cost,and in terms of morbid-
ity and mortality.
1 Addictions frequently are of early
onset,and are associated with many other psychiatric and
other medical conditions,both as cause and consequence.
According to the 2005 national survey on drug and alco-
hol by the Substance Abuse and Mental Health
Administration (SAMHSA),first-time users of alcohol,
illicit drugs,and tobacco over the age of 12 years num-
bered 4.3 million, 2.9 million, and, 2.3 million, respec-
tively.
2The relapsing/remitting nature of addictive disor-
ders,and the high frequency of suicide in addiction,are
notable features of these often lifelong disorders.
Pharmacogenetic factors modify both the vulnerability
to addiction and response to treatment,making it vital to
identify specific pharmacogenetic factors to design bet-
ter treatment and prevention strategies,and to better tar-
get those interventions (Figure 1).
Inheritance
Heritability accounts for 40% to 80% of the variation in
vulnerability to a range of addictive disorders.
3These her-
itability estimates are primarily based on a series of large
studies comparing concordance of monozygotic (identical)
and dizygotic (fraternal) twins (Figure 2).It is important
to note that heritability has been estimated from epi-
demiologically sampled twins and in age cohorts within
national or state populations.The heritabilities computed
from these studies are thus likely to reflect the average
action of genes on addiction within a population,but not
across populations or across time,where there are addi-
tional sources of environmental variance.
3 In the US,her-
itability accounts for approximately 50% of the interindi-
vidual variation in vulnerability to alcohol dependence,as
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Addictions are illnesses of complex causation, including
inheritance and a role for gene/environment interac-
tions. Functional alleles influencing pharmacodynamic
(tissue response) and pharmacokinetic (absorption, dis-
tribution, and metabolism) play a role, but these inter-
act with diverse environmental factors including early
life stress, underage drug exposure, availability of addic-
tive agents, and response to clinical interventions includ-
ing pharmacotherapies. Identification of genetic factors
in addiction thus plays an important role in the under-
standing of processes of addiction and origins of differ-
ential vulnerabilities and treatment responses.     
© 2007, LLS SAS Dialogues Clin Neurosci. 2007;9:447-454.shown by meta-analysis of large methodologically sound,
epidemiologically based twin studies augmented by fam-
ily and adoption studies.Although alcoholism and other
addictions are probably influenced by variation at many
genes,alcoholism resembles other addictions in that the
concordance ratios for risk in vulnerability are approxi-
mately 2:1 for monozygotic (MZ):dizygotic (DZ) twins,a
finding that indicates the possibility for major gene effects
and additive actions of alleles,rather than more complex
epistatic interactions that are more likely to occur in dis-
eases with high MZ:DZ concordance ratios.
3 In the addic-
tions,sex interactions in vulnerability are frequently seen.
Often,as for alcoholism and nicotine addiction,men are
at higher risk than women.However the male-to-female
ratios vary substantially worldwide,and have decreased in
many countries as women have gained access to sub-
stances,or have actually been targeted by advertising,as
in advertising campaigns for cigarettes.
4,5 For example,
alcoholism is an addiction whose prevalence varies across
culture, and has varied across time, and many drugs of
abuse (eg, nicotine, cocaine, amphetamines) have been
introduced in only the past several centuries,or even more
recently.
3The heritability of dependencies to substances
with higher addictive potential tends to be higher; for
example,opioids have high addictive potential and opioid
addiction is highly heritable—approximately 65%, as
shown by large twin studies such as the Vietnam and
World War II veterans' studies.
6
Although much is known about the heritability of addic-
tive agents, the heritabilities of dependency to many
addictive agents that are important on a worldwide basis
are unknown.Heritability studies have predominantly
been carried out in Western countries,and on substance
dependencies that are common in these countries. In
many countries,other agents play a more important role.
In several instances,the active agent is similar or identi-
cal,but delivered to the body by chewing.For example,
khat leaves harvested from the tree Catha edulis are
chewed for their euphoric properties in East Africa and
Yemen.
7,8The heritability of khat addiction may be low
or the genetics may be that of protective alleles,since in
certain regions such as Yemen 90% to 95% of males and
an increasing number of females are addicted.While the
heritability of cigarette smoking is well understood—
nicotine dependence heritability is approximately
60%
5—tobacco is often chewed in the rural US and in
other parts of the world.In Andean countries,the coca
leaf is chewed.Finally,on a worldwide basis,young peo-
ple are being exposed to video games, some Internet-
based,that frequently lead to addictive use,and the her-
itability of this addiction is unknown.
Cross-inheritance
Twin and family studies reveal that addictions are cross-
inherited as well as influenced by substance-specific fac-
tors.Several cross-transmission studies in the Vietnam
Veterans,World War II Veterans,and Virginia Adoption
study all revealed a common vulnerability factor,of vary-
ing magnitude,shared by nicotine and alcohol addiction.
In these studies, the risk of the second disorder was
higher in the co-twin of the proband with the first disor-
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Figure 1. Genetic aspects of addiction: four nonorthogonal axes of gene
action.
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Figure 2. Heritabilities (h2) of six addictive disorders. The heritabilities are
weighted means estimated by Goldman et al
3 from large twin
studies.
Adapted from ref 3: Goldman D, Oroszi G, Ducci F. The genetics of addic-
tions: uncovering the genes. Nat Rev Genetics. 2005;6:521-532.
Copyright © Nature Publishing Group 2005.
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1,287 1,930 4,348 1,302 5,664der,indicating a common underlying vulnerability factor.
The cross-inheritance explains,in part,the tendency for
certain addictions to be comorbid (to co-occur) at higher
frequencies than expected randomly.For example,it has
been reported that nearly 80% of alcoholics are heavy
smokers.
4 Comorbidity of cocaine dependence and opi-
oid addiction frequently occurs,and both are frequently
comorbid with nicotine dependence.The use of cocaine,
opiates,and amphetamine is 10 times higher in alcoholics
as compared with nonalcoholics.
9-12Addictions also tend
to be comorbid with other psychiatric diseases,and cross-
inheritance again provides part of the explanation.
13 Both
internalizing disorders—depression,anxiety—and exter-
nalizing disorders—antisocial personality disorder—
show excess comorbidity and some evidence of cross-
inheritance. The sharing of inheritance presumably
reflects the effects of the same genes on mechanisms
common to different addictions and diseases.
3
A potential role for the muscarinic acetylcholine M2
receptor gene (CHRM2) in comorbid vulnerability to
alcoholism and other drug dependencies was identified
in families with alcohol addiction in the large
Collaborative Study on the Genetics of Alcoholism
which comprises samples collected from families with
alcoholism from across six states nationwide.In a family-
based study,Schuckit et al examined the role of the mus-
carinic acetylcholine receptor (CHRM2) among individ-
uals with alcohol dependence alone and in those with
alcohol dependence and comorbid drug dependence.
Samples were collected from 2282 individuals in 262
COGA families.A total of 477 individuals had alcohol
dependence with comorbid drug dependence, and 433
individuals had alcohol dependence without comorbid
drug use.The association of CHRM2 originated entirely
in alcoholics with comorbid drug dependence. In the
alcohol-dependent group without drug dependence there
was no evidence of association to CHRM2.
12
Studies in mice indicate that the 5HT1B receptor gene,
which encodes the terminal auto receptor regulating
serotonin release, is involved in cocaine and alcohol
addiction.Mice lacking the 5HT1B receptor show height-
ened response to cocaine and alcohol and augmented
cocaine and alcohol self-administration, and mice
knocked out for the HTR1B receptor were more aggres-
sive and drank more alcohol.
14,15 In humans,HTR1B was
associated with antisocial alcoholism (alcoholism comor-
bid with antisocial personality disorder) in two popula-
tions,
16 and depression and anxiety.
17 One of the earliest
observations of cross-inheritance in addictions was the
tendency of fathers with antisocial personality disorder
to have children with alcoholism, whether or not the
child was adopted out to a family without pathology.
18
Pharmacokinetic and 
pharmacodynamic variation
Pharmacokinetic variation refers to variation in drug
absorption, distribution in the body, metabolism, and
excretion. Pharmacodynamic variation refers to the
response of the body and encompasses dose effects,
ascending and descending limb variation,sensitization
and tolerance,developmental and age effects,and genetic
variation.
The classic and well-known examples of pharmacokinetic
variation in addiction are the functional polymorphisms
of alcohol dehydrogenase 1B (ADH1B2-His47Arg)
which metabolizes alcohol to acetaldehyde and aldehyde
dehydrogenase 2 (ALDH -Glu487Lys) which metabo-
lizes acetaldehyde to acetate. Following alcohol con-
sumption, both the Arg47 and Lys487 alleles, alone or
together,can lead to the accumulation of acetaldehyde,
producing aversive flushing, nausea, and headache.
19,20
People of Southeast Asian ancestry are especially likely
to carry the ADH1BArg47 and ALDH2 Lys487 alleles,
but individuals of Jewish ancestry also often carry the
Arg47 allele.
21 Both the Arg47 and Lys487 alleles lead to
a reduction in risk of alcoholism,with a protective effect
of fourfold to tenfold in carriers,and an additive protec-
tive effect when both alleles are carried by the same per-
son.The ADH1B alleles are codominant in action but
ALDH2 Lys487 is semidominant,such that heterozygous
carriers have very low levels of ALDH2 enzyme activity.
However, ALDH2 Lys487/Lys487 homozygotes are
nearly completely protected from alcoholism.The action
of these two genetic variants has an interesting pharma-
cologic parallel.Disulfiram,which inhibits ALDH,is one
of several drugs in use for treatment of alcoholism.
Metronidazole and certain other antiprotozoal drugs also
inhibit ALDH, and also lead to the aversive flushing
reaction following ethanol ingestion.
19-22 In addition,the
Lys487 allele has been shown to be associated with
higher risk of gastrointestinal cancer after alcohol con-
sumption,and probably through the carcinogenic action
of acetaldehyde.
22
Less clear is the pharmacogenetic role of enzymes such
as catalase and cytochrome P450 2E1 (CYP2E1) that
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acetaldehyde,albeit a quantitatively more minor role.
24
Many proteins and their genes are targets for pharma-
codynamic variation in vulnerability to alcohol depen-
dence.In a prospective study of young,relatively alcohol-
naive male college students,low response to alcohol was
shown to be a predictor of alcoholism,and has been used
as a heritable intermediate phenotype,both for candidate
gene studies and for genome linkage scans.
25
Dopamine β hydroxylase (DβH) is the enzyme that con-
verts dopamine to norepinephrine.DBH exhibits inher-
ited functional variation that has been linked to various
psychiatric disorders including depression and alco-
holism.The DBH variant -1021 C>T predicts reduced
plasma DβH enzyme activity. DBH linkage studies to
nicotine are so far inconclusive.
26-29 However,Freier et al
found that individuals with the DBH -1021T allele
smoked less than -1021C/-1021C homozygotes.Equivocal
linkage data are also reported for the DRD2 dopamine
receptor,which is thought to be integral for dopamine-
mediated reinforcement.
26A “gatekeeper”for nicotine’s
central nervous system actions is the nicotine receptor.
The α4β2 heteromer is essential for nicotine’s rewarding
actions, as shown by studies in knockout mice.
27 In the
future more information is likely to be developed on the
role of functional nicotine receptor variants,which may
be rare or uncommon.
Alcohol exerts its sedative and rewarding actions in part
through stimulation of GABAA receptors and inhibition
of NMDA glutamate receptors, and key signaling pro-
teins include protein kinase C enzymes,as revealed by
a variety of studies including electrophysiology studies of
receptors and investigations on mice knocked out for
these genes.Some of these “gatekeeper”molecules have
been implicated by linkage and association studies.
Genetic linkage studies implicating GABAA subunit
genes include a series of mouse ethanol-related quanti-
tative loci (for behaviors such as alcohol preference and
sensitivity to the sedating actions of ethanol) and,in the
human,whole genome scans and linkage disequilibrium
studies linking the Chromosome 4 GABAA receptor
subunit gene complex and the GABAA 2 gene. The
Chromosome 5 GABAA receptor subunit complex and
the GABAA6 gene therein at the GABAA6 gene is
the Ser385 allele, which may correlate with LR, and a
higher risk of alcoholism and variation in response to
benzodiazepines.
30-34The GABRG1 haplotype markers
showing greater allelic,genotypic,and haplotypic associ-
ation with alcohol dependence compared with those of
haplotype block may act in a dominant manner in rela-
tion to risk of alcohol dependence.
35
The µ-opioid receptor gene OPRM1 is the most exten-
sively studied of the opioid receptor genes because of its
important role in reward mediated by endogenous opi-
oids.The functional OPRM1Asn40Asp variant of the µ-
opioid receptor gene has been shown in some studies to
be associated with opioid addiction.
36,37,38 For example,
association of this OPRM1 variant to polysubstance
abuse including opioids, cocaine, and alcohol was
reported by Kranzler et al.
36 Berrettini and colleagues
reported that the major opioid preference quantitative
trait loci in mice mapped to the location of the murine µ
opioid receptor gene.
39 OPRM1Asn40Asp has also been
variably linked to alcoholism,
29,30 and perhaps most
intriguingly,appears to alter opioid-mediated release of
cortisol,this effect on the hypothalamic-pituitary-adrenal
axis potentially revealing its action on stress activations
important in addiction.
40 A delta opioid receptor,
OPRD1,variant has also been reported to be associated
with substance dependence.
41The endogenous opioid sys-
tem is also critical to the reinforcing effects of nonopioid
drugs including nicotine,alcohol,cocaine,and cannabi-
noids.
37,42
Gene-environment interactions in addiction
Addiction is a complex disease involving the interaction
of genes and environment.The vulnerability to abuse of
addictive agents is in part determined by genetic varia-
tion and in part by environmental factors including expo-
sure to addictive agents,but also such nonspecific factors
as stress exposure early in life.
Several of the interacting genes found so far are stress-
related,modulating resiliency and vulnerability.Early life
stress exposures such as childhood sexual abuse play a
powerful but apparently nonspecific role,because such
stress also increases vulnerability to other psychiatric dis-
eases.In the rat preferring/nonpreferring (P/NP) model
of alcohol consumption,a major quantitative locus for
ethanol preference is at the site of the gene for neu-
ropeptide Y,an anxiolytic neuropeptide.In the human,
genetic variants of neuropeptide Y have sometimes,but
not always, been linked to alcoholism as well as other
behaviors, including obesity.
43,44 A catechol-O-methyl-
transferase polymorphism that predicts anxiety and cog-
nitive function has been associated with alcoholism and
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45Another stress-related gene is the
serotonin transporter, which contains the functional
HTTLPR locus. In the rhesus macaque monkey, the
reduction of function allele of the orthologous rh-
HTTLPR locus predicts enhanced alcohol consumption,
but only in the context of early life stress exposure.
46 In
humans with cocaine addiction,the already high rate of
suicide attempts is greatly increased in carriers of the
reduction of function HTTLPR allele who had a history
of childhood abuse or neglect.
47 Childhood trauma is in
general associated with depression and suicide in indi-
viduals with the 5-HTTLPR reduction of function allele.
48
A functional polymorphism in the promoter region of
monoamine oxidase A gene (MAOA) resulting in a low
expressing genotype has been found to interact with
childhood sexual abuse to increase risk of alcoholism,
and especially antisocial personality disorder (ASPD)
occurring in the context of Alcohol Use Disorders in
women.
49 Other environmental factors influencing vul-
nerability include price,availability,early life stress expo-
sures,and underage drinking.
50 For example,alcohol pro-
hibition from 1920 to 1933 in the US led to a large
decrease in alcoholism and associated cirrhosis. Also,
onset of drinking in the early adolescent or preadoles-
cent years is a strong risk factor.However,the interac-
tions of such factors with gene effects are even less well
understood.
The pharmacogenetics of pharmacotherapy
Treatment of addiction encompasses two main phases:
acute detoxification and maintenance. Maintenance
treatment is aimed at maintaining abstinence,or harm
reduction.Supportive therapy plays a vital role and this
may include cognitive therapy and self-help groups.
Categories of pharmacotherapeutics include:
• Detoxification (eg,benzodiazepines in alcoholism and
clonidine in opiate withdrawal )
•Agonist (eg,methadone,levo-alpha-acetyl-methadol
(LAAM]) 
• Partial agonist (eg,buprenorphine for opioid addiction)
•Antagonist (eg,naltrexone in alcoholism)
•Anticraving (eg,bupropion and homotaurine in alco-
holism)
•Aversive (eg,disulfiram).
Because each of these drugs targets specific proteins and
small molecules,there is considerable potential for spe-
cific pharmacogenetics of treatment response.Each of
these drugs is also subject to metabolism, leading to a
role for pharmacogenetic variation such as the
cytochrome p450 2‚6 which predicted response to bupro-
pion in nicotine dependence.
51The OPRM1Asn40Asp
polymorphism has,in addition to its disease associations,
also been associated with naltrexone treatment response
in alcoholism and as recently replicated in a large clini-
cal trial,the COMBINE study.
52The role of OPRM1 in
smoking has been studied in relation to nicotine replace-
ment therapy.Nicotine increases the release of β-endor-
phins indirectly releasing dopamine and leading to plea-
surable sensations associated with smoking,as shown by
several studies both in rats and humans.In a randomized
study,320 smokers of European ancestry were treated
with a nicotine transdermal patch or nasal spray over a
6-month period and 41% of Asp40 carriers remained
abstinent at the end of 6 months as compared with 30%
of Asn40/Asn40 homozygotes.
53 However,the effect of
genotype disappeared after treatment cessation.Another
gene that may predict nicotine treatment response is
cytochrome P450 2B6 (CYP2B6) which predicted treat-
ment response with bupropion,which is metabolized by
this enzyme. In a study of 426 smokers of European
ancestry,participants with the low activity allele reported
increased craving and higher relapse rate.This effect may
also be attributable to slower nicotine metabolism.
51
Finally, there are genetic factors that are likely to act
across different drugs used in treatment and even differ-
ent diseases,to predict treatment response.These may
include genes that influence anxiety and stress response
such as COMT, NPY, and 5-HTTLPR, as discussed
above.They may also include genes altering cognitive
function,such as COMT which predicts executive cogni-
tion.
54,55 One such functional polymorphism is the
Met66Val polymorphism of the brain-derived neu-
rotrophic factor gene (BDNF), which predicts hip-
pocampal volumes and episodic memory function.
56At
present,none of the genetic markers available has found
application in clinical practice.The OPRM1Asn40Asp
polymorphism presently has potential for immediate util-
ity in both alcoholism and nicotine addiction treat-
ment.
52,57,58
Concerning methadone treatment,human genetic varia-
tion may offer an advantage to this treatment modality
for opioid addictions, many identified variants of
CYP2D6,which metabolizes codeine,have been shown
to alter levels of active codeine metabolites such as oxy-
codone and hydrocodone, potentially altering risk of
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metabolizes methadone,buprenorphine,and LAAM,has
not been found to have functional variants to affect
metabolism of these opiates.
38
The role of CB1 cannabinoid receptors role in the reward
system make them a treatment target for drugs of abuse
such as cannabinoids,opiates,and nicotine,and recently
rimonabant has been utilized,but the role of genetic vari-
ation is unknown.Since the modes of action of certain
drugs used or proposed for use in treatment including
acamprosate
59 and topiramate
60 is unknown,the pharma-
cogenetic gene targets are also unclear.However,in cer-
tain instances, treatment suitability may be defined by
general clinical features and the genes influencing these
features. For example, serotonergic abnormalities are
thought to be important in early-onset alcoholics, and
ondansetron,which targets 5-HT (serotonin)3 receptors,
selectively reduced craving in early onset alcoholics as
compared with late-onset alcoholics.Finally,variation is
being uncovered in genes,such as BDNF,that mediate
neuronal signaling and plasticity,and functional loci such
as BDNF Met66Val may potentially be critical to long-
term recovery. In the future, genetic tools are likely to
become increasingly useful to increase specificity of diag-
nosis and to develop and better target treatments. ❏
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Aspectos farmacogenéticos de las conductas
adictivas
Las adicciones son enfermedades de compleja causa-
lidad en que se incluyen la herencia y el papel de las
interacciones entre los genes y el ambiente. Los ale-
los funcionales que afectan la farmacodinámica (res-
puesta tisular) y la farmacocinética (absorción, distri-
bución y metabolismo) también tienen un papel, pero
estos interactúan con diversos factores ambientales
como situaciones de estrés de vida precoces, exposi-
ción a drogas de los menores de edad, disponibilidad
de sustancias adictivas y respuesta a intervenciones clí-
nicas (incluyendo las terapias farmacológicas). La iden-
tificación de factores genéticos en la adicción juega
un papel importante para la comprensión de los pro-
cesos adictivos y de los orígenes de las vulnerabilida-
des y respuestas al tratamiento individuales.  
Aspects pharmacogénétiques des 
comportements addictifs
Les addictions sont des maladies aux causes com-
plexes, dont font partie l’hérédité et les interactions
gène/environnement. Les allèles fonctionnels influant
sur la pharmacodynamique (réponse tissulaire) et la
pharmacocinétique (absorption, distribution et méta-
bolisme) jouent un rôle mais ils interagissent avec
divers facteurs environnementaux comme les stress
de vie précoces, l’exposition des mineurs aux médi-
caments, la disponibilité des produits addictogènes
et la réponse aux interventions cliniques y compris les
pharmacothérapies. L’identification des facteurs
génétiques dans l’addiction joue donc un rôle impor-
tant dans la compréhension du processus d’addiction
et des origines des différences de vulnérabilité et de
réponse thérapeutique.
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